PE20060239A1 - Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonista enantiomericamente puros - Google Patents

Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonista enantiomericamente puros

Info

Publication number
PE20060239A1
PE20060239A1 PE2005000530A PE2005000530A PE20060239A1 PE 20060239 A1 PE20060239 A1 PE 20060239A1 PE 2005000530 A PE2005000530 A PE 2005000530A PE 2005000530 A PE2005000530 A PE 2005000530A PE 20060239 A1 PE20060239 A1 PE 20060239A1
Authority
PE
Peru
Prior art keywords
hydroxy
inhalation
enanthomerically
agonist
contain
Prior art date
Application number
PE2005000530A
Other languages
English (en)
Inventor
Michael Trunk
Jorg Schiewe
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35058202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20060239A1 publication Critical patent/PE20060239A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UNA FORMULACION EN POLVO PARA INHALACION QUE CONTIENE: A) UN COADYUVANTE FISIOLOGICAMENTE TOLERADO SELECCIONADO ENTRE MONOSACARIDOS, DISACARIDOS, OLIGOSACARIDOS, ENTRE OTROS; B) UN COMPUESTO DE FORMULA I, DONDE R1, R2 Y R4 SON CADA UNO H, ALQUILO C1-C4, ALCOXI C1-C4, HALOGENO; R3 ES H, ALQUILO C1-C4, ALCOXI C1-C4, OH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS EN LA FORMULACION: HIDROCLORURO DE 6-HIDROXI-8-{(R)-1-HIDROXI-2-[2-(4-METOXI-FENIL)-1,1-DIMETIL-ETILAMINO]-ETIL}-4H-BENZO[1,4]OXAZIN-3-ONA; HIDROCLORURO DE 8-{(R)-2-[2-(2,4-DIFLUORO-FENIL)-1,1-DIMETIL-AMINO]-1-HIDROXI-ETIL}-6-HIDROXI-4H-BENZO[1,4]OXAZIN-3-ONA; HIDROCLORURO DE 8-{(R)-2-[2-(4-ETOXI-FENIL)-1,1-DIMETIL-ETILAMINO]-1-HIDROXI-ETIL}-6-HIDROXI-4H-BENZO[1,4]OXAZIN-3-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON BETA-AGONISTAS UTILES EN EL TRATAMIENTO DE LAS ENFERMEDADES DE LAS VIAS RESPIRATORIAS
PE2005000530A 2004-05-14 2005-05-12 Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonista enantiomericamente puros PE20060239A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004024451A DE102004024451A1 (de) 2004-05-14 2004-05-14 Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten

Publications (1)

Publication Number Publication Date
PE20060239A1 true PE20060239A1 (es) 2006-03-27

Family

ID=35058202

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000530A PE20060239A1 (es) 2004-05-14 2005-05-12 Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonista enantiomericamente puros

Country Status (24)

Country Link
EP (1) EP1809236B1 (es)
JP (1) JP4891899B2 (es)
KR (1) KR101270449B1 (es)
CN (1) CN1984638A (es)
AR (1) AR048899A1 (es)
AU (1) AU2005244424B2 (es)
BR (1) BRPI0511136A (es)
CA (1) CA2565915C (es)
DE (1) DE102004024451A1 (es)
DK (1) DK1809236T3 (es)
EA (1) EA012582B1 (es)
ES (1) ES2401786T3 (es)
IL (1) IL179215A (es)
MX (1) MXPA06013221A (es)
MY (1) MY145838A (es)
NO (1) NO20065078L (es)
PE (1) PE20060239A1 (es)
PL (1) PL1809236T3 (es)
SG (1) SG152258A1 (es)
TW (1) TW200607508A (es)
UA (1) UA86807C2 (es)
UY (1) UY28896A1 (es)
WO (1) WO2005110359A1 (es)
ZA (1) ZA200607785B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004024452A1 (de) * 2004-05-14 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolformulierung für die Inhalation von Betaagonisten
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP1924553A1 (en) 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
AU2006281449B2 (en) * 2005-08-15 2013-01-31 Boehringer Ingelheim International Gmbh Method for producing betamimetics
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SG172444A1 (en) 2008-12-30 2011-07-28 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2014056840A1 (en) 2012-10-09 2014-04-17 Boehringer Ingelheim International Gmbh Beta-2-adrenoceptor agonist for the treatment of cough
CN110062625A (zh) 2016-12-12 2019-07-26 勃林格殷格翰国际有限公司 尼达尼布通过与奥达特罗共给予用于治疗间质性肺病的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3134590A1 (de) * 1981-09-01 1983-03-10 Boehringer Ingelheim KG, 6507 Ingelheim Neue benzo-heterocyclen
US4460581A (en) * 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE4318455A1 (de) 1993-06-03 1994-12-08 Boehringer Ingelheim Kg Kapselhalterung
PL362868A1 (en) * 2000-04-27 2004-11-02 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel, slow-acting betamimetics, a method for their production and their use as medicaments
GB0107106D0 (en) * 2001-03-21 2001-05-09 Boehringer Ingelheim Pharma Powder inhaler formulations
DE10141377A1 (de) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
UA80123C2 (en) 2002-04-09 2007-08-27 Boehringer Ingelheim Pharma Inhalation kit comprising inhalable powder of tiotropium
DE10253282A1 (de) * 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung

Also Published As

Publication number Publication date
SG152258A1 (en) 2009-05-29
WO2005110359A1 (de) 2005-11-24
AU2005244424A1 (en) 2005-11-24
BRPI0511136A (pt) 2007-11-27
CA2565915C (en) 2013-12-10
IL179215A0 (en) 2007-03-08
CA2565915A1 (en) 2005-11-24
PL1809236T3 (pl) 2013-05-31
ZA200607785B (en) 2008-07-30
NO20065078L (no) 2006-11-28
EP1809236B1 (de) 2012-12-26
MXPA06013221A (es) 2007-02-08
JP2007537195A (ja) 2007-12-20
MY145838A (en) 2012-04-30
EA200602016A1 (ru) 2007-06-29
JP4891899B2 (ja) 2012-03-07
KR20070016169A (ko) 2007-02-07
DK1809236T3 (da) 2013-02-11
EP1809236A1 (de) 2007-07-25
AR048899A1 (es) 2006-06-07
KR101270449B1 (ko) 2013-06-04
DE102004024451A1 (de) 2005-12-22
AU2005244424B2 (en) 2010-12-23
ES2401786T3 (es) 2013-04-24
EA012582B1 (ru) 2009-10-30
TW200607508A (en) 2006-03-01
IL179215A (en) 2011-04-28
UY28896A1 (es) 2005-12-30
UA86807C2 (ru) 2009-05-25
CN1984638A (zh) 2007-06-20

Similar Documents

Publication Publication Date Title
PE20060239A1 (es) Formulaciones en polvo para la inhalacion, las cuales contienen beta-agonista enantiomericamente puros
PE20040694A1 (es) Derivados de benzoxazolinonas
RU2501799C2 (ru) Поизводные оксазолидинона
PE20070708A1 (es) Formulacion en aerosol para inhalacion de beta-agonistas
PE20081319A1 (es) Formulacion de aerosol para la inhalacion de agonistas beta
ES2298993T3 (es) Nuevos agonistas beta-2-de efecto prolongado y su uso como medicamentos.
PE20060462A1 (es) Combinacion farmaceutica que comprende derivados de benzoxazinona
NO20073853L (no) Faste, oralt applikerbare farmasoytiske administreringsformer inneholdende nvaroksaban med modifisert frigivelse
WO2009031011A3 (en) Xinafoate salt of n4-(2, 2-difluoro-4h-benz0 [1,4] 0xazin-3-one) -6-yl] -5-fluoro-n2- [3- (methylaminocar bonylmethyleneoxy) phenyl] 2, 4-pyrimidinediamine
NO20052914L (no) Terapeutiske forbindelser
RU2007147413A (ru) Аминопиперидинхинолины и их азаизостерические аналоги с антибактериальной активностью
PE20080607A1 (es) Formulacion en aerosol para la inhalacion de beta-agonistas
PE20091384A1 (es) Compuestos tienopirimidina y pirazolopirimidina como inhibidores de quinasa mtor y quinasa p13
NZ542622A (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
PE20011119A1 (es) Composiciones farmaceuticas de agonista/antagonista de estrogenos para el tratamiento de afecciones que responden a un aumento de testosterona
KR20080065704A (ko) 의학적 이상의 치료 방법들, 조성물들, 및 키트들
JP2007537187A5 (es)
PE20080056A1 (es) Derivados de cromencarboxamida como antagonistas del receptor s1p1
RU2008110917A (ru) ПРОИЗВОДНЫЕ 7-(2-АМИНО-1-ГИДРОКСИ-ЭТИЛ)-4-ГИДРОКСИБЕНЗОТИАЗОЛ-2(3Н)-ОНА В КАЧЕСТВЕ АГОНИСТОВ β2-АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ
JP2009531435A (ja) うつ病の治療用の新規な治療組み合わせ
WO2006027378A1 (en) Roflumilast and syk inhibitor combination and methods of use thereof
AR048197A1 (es) Metodos para tratar la esquizofrenia y/o anomalias de glucorregulacion
JP2008512428A5 (es)
BRPI0617269A2 (pt) combinações de medicamentos e seus usos para tratamento de doenças das vias respiratórias
JP2008508359A5 (es)

Legal Events

Date Code Title Description
FC Refusal